or Try an Advanced Search...

    Technical Analysis for CYTH - Cyclo Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.20 -5.51% -0.07
    CYTH closed down 5.51 percent on Monday, July 1, 2024, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CYTH trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    180 Bearish Setup Bearish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Crossed Above 20 DMA Bullish -5.51%
    Pocket Pivot Bullish Swing Setup -5.51%
    Bollinger Band Squeeze Range Contraction -5.51%
    BB Squeeze Started Range Contraction -5.51%
    Older End-of-Day Signals for CYTH ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 6 hours ago
    Possible NR7 about 6 hours ago
    Possible Inside Day about 6 hours ago
    Down 5% about 7 hours ago
    Fell Below 10 DMA about 7 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    CYTH Chart by TradingView
    Basic chart:

    Profile

    Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease. The company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease. Additional indications for the active ingredient in Trappsol Cyclo are in development.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Clinical Medicine Rare Diseases Alzheimer's Disease Lipid Storage Disorders

    Is CYTH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 25 Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
    Jun 14 Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
    May 30 Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
    May 16 Cyclo Therapeutics reports Q1 results
    May 16 Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    Apr 10 Pleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics Stock
    Mar 18 Cyclo Therapeutics reports FY results
    Mar 18 Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    Mar 14 Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
    Mar 13 Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
    See more CYTH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.1242
    52 Week Low 0.8924
    Average Volume 30,353
    200-Day Moving Average 1.42
    50-Day Moving Average 1.32
    20-Day Moving Average 1.24
    10-Day Moving Average 1.22
    Average True Range 0.10
    RSI (14) 44.75
    ADX 11.76
    +DI 17.25
    -DI 16.27
    Chandelier Exit (Long, 3 ATRs) 1.08
    Chandelier Exit (Short, 3 ATRs) 1.40
    Upper Bollinger Bands 1.32
    Lower Bollinger Band 1.16
    Percent B (%b) 0.27
    BandWidth 13.14
    MACD Line -0.03
    MACD Signal Line -0.04
    MACD Histogram 0.0043
    Fundamentals Value
    Market Cap 34.31 Million
    Num Shares 28.6 Million
    EPS -1.59
    Price-to-Earnings (P/E) Ratio -0.75
    Price-to-Sales 51.42
    Price-to-Book 1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.30
    Resistance 3 (R3) 1.32 1.29 1.29
    Resistance 2 (R2) 1.29 1.27 1.29 1.28
    Resistance 1 (R1) 1.25 1.25 1.23 1.23 1.28
    Pivot Point 1.22 1.22 1.22 1.22 1.22
    Support 1 (S1) 1.18 1.20 1.17 1.17 1.12
    Support 2 (S2) 1.15 1.18 1.15 1.12
    Support 3 (S3) 1.11 1.15 1.11
    Support 4 (S4) 1.10